Solid Biosciences Inc.SLDBNASDAQ

Revenue (LTM)

Net Income (LTM)

$-174M

-39.8% YoY

Free Cash Flow

$-157M

Revenue CAGR (5Y)

—

—Marginsstable

FCF($0.2B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	14	8↓40.6%	0	0	0
Gross Profit	14	8↓40.6%	-3↓131.9%	-2↑4.9%	-2↑33.4%
Operating Income	-72	-106↓47.3%	-104↑2.0%	-130↓24.4%	-179↓38.1%
Net Income	-72	-86↓19.1%	-96↓11.7%	-125↓29.9%	-174↓39.8%
EBITDA	-69	-97↓39.8%	-93↑3.5%	-122↓30.5%	-179↓47.0%
EPS Diluted	-10.14	-10.10↑0.4%	-4.83↑52.2%	-3.06↑36.6%	-1.99↑35.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	119	155↑30.4%	74↓52.4%	80↑8.4%	60↓25.3%
Total Current Assets	223	220↓1.3%	130↓40.9%	157↑21.2%	205↑30.6%
Total Assets	232	260↑12.0%	165↓36.6%	189↑14.4%	233↑23.3%
Total Current Liabilities	24	23↓4.6%	15↓35.5%	30↑108.4%	33↑10.6%
Total Liabilities	24	49↑101.0%	38↓20.8%	51↑33.7%	53↑2.2%
Total Equity	208	212↑1.7%	126↓40.2%	137↑8.5%	180↑31.2%
Total Debt	2	29↑1283.8%	26↓8.0%	24↓7.9%	21↓12.5%
Net Debt	-117	-127↓8.3%	-48↑62.4%	-56↓17.4%	-39↑30.9%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-78	-98↓26.0%	-94↑3.9%	-100↓6.2%	-156↓56.3%
Capital Expenditure	-1	-3↓135.4%	-2↑49.8%	-1↑56.8%	-1↓76.3%
Free Cash Flow	-79	-101↓27.8%	-96↑5.2%	-101↓5.2%	-157↓56.4%
Stock-Based Comp	13	8↓43.6%	8↑1.2%	11↑38.0%	17↑60.8%
Net Change in Cash	-34	36↑206.3%	-81↓326.0%	6↑107.8%	-20↓420.2%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance